Market research in the cannabis sector is higher than that of any other industry. A search for cannabis market data will return dozens of reports, forecasts, and dashboards — many priced at thousands of dollars, most making bold claims about market size and growth trajectories.
The quality difference between the top and bottom cannabis research providers is huge, and it is costly to make decisions on the basis of poor data. This guide was created to assist investors, analysts, and operators in evaluating what they are buying.
Cannabis Market Research is Uniquely Difficult
Standardised data infrastructure is common in most industries. IMS Health is the pharmaceutical market’s data infrastructure. Nielsen has consumer products. Bloomberg has the data on stocks. Cannabis has none of these — and the reasons matter for anyone consuming cannabis market data.
There are many different regulatory structures at the national and subnational levels. Each has different requirements for reporting, different descriptions of “medical” and “recreational,” as well as wildly varying transparency. There is no national database in the United States due to federal law. In Europe, each country’s health authority collects and publishes data differently — some monthly, some annually, some not at all.
Two problems arise from this fragmentation for cannabis market researchers. There are few providers who can produce data that is truly rigorous. The second problem is that the barrier to produce plausible but poor-quality data is low. This means there are a lot of reports on the market which look credible but aren’t.
It is important for those who are involved in commercial cannabis to understand the difference between these categories.
Cannabis Market Research Landscape
Four categories of providers are available, with each having different strengths, limitations and uses.
Generic Market Research Companies — publish cannabis reports as part of their coverage of hundreds of industries. The reports usually offer a broad market size for the global or regional markets, as well as segmentation of products and regions, along with high-level forecasts on CAGR. These reports are helpful for initial orientation, and procurement teams that need an independent number of market size for a business plan. The reports lack depth. Analysts who write these are usually generalists, covering many different sectors. Methodology sections can be vague and data sources rarely detailed. For a single study, prices range between $3,000 and $5,000.
Cannabis-specialist data platforms — focus exclusively on the cannabis sector and offer subscription-based access to ongoing data feeds. As an example, the Headset platform tracks the data of over 3,500 retailers in North America, tracking point-of sale. This allows for real-time insights into customer purchasing habits, brand performance trends and pricing. The platforms excel at operational and retail intelligence, especially in North American market. Their limitation is geographic: coverage outside North America is limited, and the European medical cannabis market — where most of the regulatory and commercial action is happening in 2026 — is largely outside their scope.
Providers of industry news and intelligence — such as MEDCAN24 and Cannabis Health News — publish ongoing market coverage, data snapshots, and periodic deep-dive analyses. This is a great way to stay up-to-date and gain a contextual understanding of the market that data alone can’t provide. The trade-off is that their coverage is typically broader than deep — a quarterly market update will give you the headline numbers, but not necessarily the granular monthly dataset you need for financial modelling.
Specialist research & analysis publishers — including Prohibition Partners — produce focused, single-market or single-topic reports designed for professional decision-making. The quality of these reports varies greatly, but they are all distinguished by transparent methodologies, primary data sources, and analytic depth beyond simple size and forecast summaries. These reports typically cost less than the generic firm offerings (£300–£1,000 vs $3,000–$5,000) and deliver more actionable intelligence for the specific markets they cover.
How to Assess a Cannabis Market Research Report
Table of Contents or Executive Summary may not be able to reveal the important differences. Here is what to look for — and what to question — when evaluating cannabis market intelligence.
How do you get your data? It is often the most difficult question to answer. Be cautious when a report cites “proprietary model” or industry estimates without specifying the original data source. Data from government or regulatory agencies is the gold standard: records of pharmacy dispensing, statistics on import/export from health authorities and licensing information from regulatory bodies. The data is verifiable, auditory, and does not have the same sampling biases as survey-based, or POS-based, approaches.
Prohibition Partners Poland Medical Cannabis Market Review for instance, was built using dispensing data obtained from Centrum e-Zdrowia – Poland’s official national authority on health information. Each data point can be traced back to its original government source. That level of provenance is rare in cannabis market research, and it matters — especially when the numbers are being used to inform investment decisions or board-level strategy.
What is the source of data? Many cannabis reports use secondary data sources to model or estimate their market statistics, rather than primary systems. There is nothing inherently wrong with modelling — all forecasts involve it — but buyers should understand the distinction. It is false to present estimated modelled data as observed. Reports that separate historical observed data from estimated or projected figures and explain any modelling assumptions are the best to look for.
How finely granular are the data? The annual market size is useful as a guide but not for making decisions. The monthly and quarterly data reveal patterns which annual aggregates do not: the seasonality of the market, impact of regulatory change, price trends and demand trajectories. You need sub-annual time series data to evaluate a pricing strategy or an investment thesis. If the report includes this information, ask how many years it spans.
Are you able to work with data or only read it? It is a distinction that’s often overlooked. Many reports deliver data as static figures embedded in a PDF — useful for reading, but not for analysis. You need data that is in an easily accessible format if you want to create your own scenarios or adjust assumptions. The quality of Excel workbooks that are delivered by some providers varies. It is important to check if the Excel workbook has live formulas you can modify or tracing.
For example, the Poland Medical Cannabis market review comes with an Excel workbook that contains hundreds of formulas based on 84 months’ worth of data. Every calculated value — growth rates, FX-adjusted figures, price per gram — is a formula you can trace back to the source data and modify for your own analysis. This is fundamentally different from a pdf with charts.
Is the analysis able to explain not only what, but why? Market research that is most useful does not limit itself to numbers. They are contextualised. It is helpful to have a report which tells us that Poland’s marijuana market will dispense 5,450 kg of cannabis in 2025. A report that explains how a telemedicine ban halved prescription volumes in late 2024, how the market restructured around physical clinics through 2025, and how prices compressed 28% as competitive dynamics shifted — that is the difference between data and intelligence.
What is the process of forecasting? Do not believe single-point projections of a smooth, long-term growth. The cannabis market is subject to regulatory changes, policy shifts, and competition disruptions which make single-point estimates inaccurate. Consider scenario-based predictions that present multiple outcomes based on different assumptions (base line, bull or bear). This approach is both more realistic and helpful for planning.
What Cannabis Market Research Costs — and What You Should Expect
Cannabis market research prices range widely, and higher price does not always equate to higher quality. In general:
Generic global or regional reports from the large market research firms typically cost $3,000–$5,000 or more. The reports provide market segmentation and sizing, but they are not as detailed on a single market. These are best suited for teams who need to present a credible number from a third party for an investor or business presentation. They’re less helpful for making operational decisions.
Specialist single-market reports from cannabis-focused publishers range from roughly £300 to £1,000. These reports offer deeper analyses, primary data and working datasets at a fraction the price of generic alternatives. These are best suited for those teams who make specific decisions about market entry, investments, and strategy in their covered markets.
Subscription data platforms typically charge $10,000–$50,000+ annually for ongoing access. They are most suitable for large operators or multi-state operators. Investors who require continuous data in real time across many markets will also benefit from these platforms. Focused reports are usually cheaper for small teams, or questions that only concern a specific market.
It isn’t important to ask “which option is the most affordable.” The key question is not “what’s the cheapest option” but rather, “what data format and detail will I require to make my decision?” A $4,000 generic report and a £399 specialist report may both contain useful information, but for a specific question — like “what is the realistic revenue trajectory for a cannabis import business targeting Poland?” — the specialist report will almost always deliver more actionable intelligence.
Important Markets in 2026
In 2026 the following markets will be the ones that generate the highest demand for cannabis research.
Germany — Europe’s largest medical cannabis market, estimated at around €670 million, is navigating proposed restrictions on telemedicine prescribing and mail-order dispensing that could significantly reshape the sector. For investors and operators, it is important to understand what impact the proposed restrictions may have on their business.
Poland — The third-largest European medical cannabis market and the only one with granular enough data to model the full impact of telemedicine restrictions. Poland’s dataset of 84 months, which covers the entire cycle, from regulatory shock to telemedicine growth, has become a reference for other European markets.
Australia — A rapidly growing medical cannabis market facing its own mounting scrutiny of telemedicine-driven prescribing models, with regulatory tightening expected through 2026.
United States — The rescheduling of cannabis from Schedule I to Schedule III, initiated by executive order in late 2025, has significant implications for taxation (removing the burden of Section 280E), banking access, and market structure. US legal cannabis sales remain the biggest in the world.
United Kingdom — A small but growing medical cannabis market where private telemedicine clinics drive the majority of prescriptions. Investors continue to pay attention to regulatory and access developments.
Prohibition Partners Reports
Prohibition Partners provides focused market intelligence to professionals involved in the cannabis business. Our reports are built on primary-source data, transparent methodology, and analytical depth — not generic templates.
Poland Medical Cannabis Market Review by 2026 — The most comprehensive analysis of Poland’s medical cannabis market available. 84 months of government-source data, the complete telemedicine ban shock-and-recovery story, pricing dynamics, and three-scenario 2026–2027 forecasts. This includes an interactive Excel worksheet with hundreds of formulas. From £399.
Browse all Prohibition Partners reports →